Efficacy and safety of eculizumab in patients with anti-glomerular basement membrane disease: an investigator-initiated, open-label, phase II clinical trial

Clicks: 9
ID: 337379
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #149 of 150 articles by views in nephrology dialysis transplantation

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 150 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Anti-glomerular basement membrane disease (GBM) is the most severe type of autoimmune kidney diseases, and is associated with the overactivation of the complement cascade. We aimed to evaluate the efficacy and safety of eculizumab, a complement C5 blocker that targets terminal pathways, in patients with anti-GBM disease. METHODS: An investigator-initiated, open-label, phase II clinical trial was conducted (NCT06513338). Eligible participants were aged at least 18 years diagnosed with anti-GBM disease at our center. Eculizumab was given at a dose of 900 mg for 4 consecutive weeks, followed by 1200 mg every other week for the subsequent 8 weeks. All patients received standard of care of the disease. The primary endpoint was end-stage kidney disease (ESKD) events at 6 months. Patients with anti-GBM disease diagnosed at the same center during the same period who did not receive eculizumab were retrospectively identified as contemporaneous controls. RESULTS: Between March 2024 and April 2025, a total of 16 patients were enrolled to receive eculizumab treatment, along with 40 contemporaneous controls. ESKD events were 25.0% at 6 months following eculizumab treatment, compared to that of 52.5% in contemporaneous controls. Of 7 patients requiring dialysis, 3 (42.9%) achieved kidney function recovery, compared to that of 8.7% in contemporaneous controls. Eculizumab treatment was associated with improved kidney function injury, while complement inhibition was evidenced by decreased urinary C5a and soluble C5b-9 concentrations and plasma CH50. Adverse events were reported in 2 participants and others showed well tolerance to eculizumab administration during the trial. CONCLUSIONS: Eculizumab treatment showed improvement in kidney survival and kidney function recovery in addition to standard of care. Eculizumab was generally well tolerated in patients with anti-GBM disease. Given the exploratory nature and sample size of this study, larger, adequately powered prospective studies are warranted to confirm and extend these findings.
Reference Key
openalex_W7223897538 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Huang Kuang, Xiao- yu Jia, Pei Chen, Meng‐Rui Li, Fang Wang, Hong Anh Chu, Chen Wang, Meng Tan, Jing Huang, Di Song, Ying Cong Ryan Shea Tan, Liu Bai Li, Yang Li, Xi-zi Zheng, Su- fang Shi, Rong Xu, Li-jun Liu, Zhao Cui, Ming-hui Zhao
Are you one of these authors? Claim your profile
Journal nephrology dialysis transplantation
Year 2026
DOI
10.1093/ndt/gfag254
URL
https://doi.org/10.1093/ndt/gfag254
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.